Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial

Neurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on different axonal pathobiologies. We aimed to test the efficacy of these drugs in...

Full description

Saved in:
Bibliographic Details
Published in:Lancet neurology Vol. 19; no. 3; pp. 214 - 225
Main Authors: Chataway, Jeremy, De Angelis, Floriana, Connick, Peter, Parker, Richard A, Plantone, Domenico, Doshi, Anisha, John, Nevin, Stutters, Jonathan, MacManus, David, Prados Carrasco, Ferran, Barkhof, Frederik, Ourselin, Sebastien, Braisher, Marie, Ross, Moira, Cranswick, Gina, Pavitt, Sue H, Giovannoni, Gavin, Gandini Wheeler-Kingshott, Claudia Angela, Hawkins, Clive, Sharrack, Basil, Bastow, Roger, Weir, Christopher J, Stallard, Nigel, Chandran, Siddharthan, Gandini Wheeler-Kingshott, Claudia A.M., Williams, Thomas, Beyene, Tiggy, Bassan, Vanessa, Zapata, Alvin, Lyle, Dawn, Cameron, James, Mollison, Daisy, Colville, Shuna, Dhillon, Baljean, Weir, Christopher J., Parker, Richard A., Gnanapavan, Sharmilee, Nicholas, Richard, Rashid, Waqar, Aram, Julia, Ford, Helen, Overell, James, Young, Carolyn, Arndt, Heinke, Duddy, Martin, Guadagno, Joe, Evangelou, Nikolaos, Craner, Matthew, Palace, Jacqueline, Hobart, Jeremy, Paling, David, Kalra, Seema, McLean, Brendan
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01.03.2020
Elsevier Limited
Lancet Pub. Group
Subjects:
ISSN:1474-4422, 1474-4465, 1474-4465
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first